NCT01208051 · Interventional trial
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
Overall registry status Completed
Phase 1 · Phase 2
Conditions Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Unresectable Thyroid Gland Carcinoma
Delaware Valley sites
- Fox Chase Cancer Center · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory